THE EFFECT OF INTRANASAL NEDOCROMIL SODIUM ON VIRAL UPPER RESPIRATORY-TRACT INFECTIONS IN HUMAN VOLUNTEERS
THE EFFECT OF INTRANASAL NEDOCROMIL SODIUM ON VIRAL UPPER RESPIRATORY-TRACT INFECTIONS IN HUMAN VOLUNTEERS
复制标题
DOI：
10.1111/j.1365-2222.1990.tb02774.x
复制
发表时间：
1990-01-01
影响因子：
6.1
通讯作者：
TYRRELL, DAJ
中科院分区：
文献类型：
--
作者：
BARROW, GI;HIGGINS, PG;TYRRELL, DAJ
两项涉及人类志愿者的双盲组比较试验的研究比较了鼻内奈多罗米钠（每鼻孔 2.6 毫克活性药物，每日一次）与安慰剂对与普通感冒相关的临床症状和表现障碍的影响。在第一项研究中，志愿者接受了鼻病毒（RV9 和 RV14）的攻击，在第二项研究中，志愿者接受了呼吸道冠状病毒的攻击。在这两项研究中，主动组和安慰剂组的志愿者在人口统计学上相似。两组的感染率也相似。没有出现因与这两种治疗相关的常见症状而退出的情况。在鼻病毒研究中（19，安慰剂；20，奈多罗米钠）每日症状评分和每日平均鼻分泌物重量在奈多罗米钠治疗组中显着较低。在冠状病毒研究中（26，安慰剂；27，奈多罗米钠），活性治疗组和安慰剂治疗组之间的感冒严重程度几乎没有差异，但趋势有利于奈多罗米钠。在这两项研究中，接受奈多罗米钠治疗的志愿者患感冒后的表现受损程度明显低于接受安慰剂治疗的志愿者。
Two studies involving double-blind group comparative trials in human volunteers compared the effects of intranasal nedocromil sodium (2.6 mg active drug per nostril, q.i.d.) with placebo on clinical symptoms and performance impairment associated with the common cold. In the first study volunteers were challenged with rhinoviruses (RV9 and RV14), and in the second study with respiratory coronavirus. In both studies, active and placebo groups of volunteers were demographically similar. Infection rates in both groups were also similar. There were no withdrawals resulting from ususual symptoms related to either treatment. In the rhinovirus study (19, placebo; 20, nedocromil sodium) daily symptom scores and daily mean nasal secretion weights were significantly lower in the nedocromil sodium-treated group. In the coronavirus study (26, placebo; 27, nedocromil sodium) there was little difference in the severity of colds between the active and placebo-treated groups, but trends favoured nedocromil sodium. In both studies the impairment of performance in volunteers who developed a cold was significantly less in those treated with nedocromil sodium than in those treated with placebo.